Covista Inc. Common Shares (CVSA)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn good returns on capital, convert profits into cash, and sell at a sensible price. Covista operates healthcare education through Chamberlain, Walden, and Medical and Veterinary. That field can have accreditation and regulatory barriers, but the numbers must prove the moat. FairStock calculates ROE of 18.57% and ROCE of 8.45%; the former is attractive, the latter only modest. Free cash flow is $392.7M trailing twelve months, an 8.9% FCF yield, which is real cash. The balance sheet is not fragile: D/E 0.63 and Altman Z 3.39. Growth is mixed. In fiscal FY2026, the year ended 2026-06-30, filed revenue was $2.0B, net income $251.6M, and diluted EPS $7.04; in fiscal FY2025, the year ended 2025-06-30, it was $1.8B, $237.1M, and $6.18; in fiscal FY2024, the year ended 2024-06-30, it was $1.6B, $136.8M, and $3.39. Long term that is impressive, and the Lynch screen calls it a FAST GROWER on 29.1% five-year profit growth and 16.8% revenue growth. But in fiscal Q3 2026, the quarter ended 2026-03-31, revenue was $487.0M and net income $41.6M, versus fiscal Q3 2025, the quarter ended 2025-03-31, revenue $466.1M and net income $60.8M. Revenue rose about 4.5%, yet profit fell about 31.6%. At the 2026-10-13 close of $129.14, FairStock's P/E is 17.24 and P/B 3.04. Its Graham Number is $84.62, so the price is about 52.6% above that conservative figure. I would call this a decent cash-generating business with a cloudy near-term earnings trend, not a bargain.

In plain English: Covista is a healthcare education company that offers nursing, medical, and veterinary programs. The business is profitable and generates cash, but latest quarterly profit fell sharply even though revenue rose. At the recent share price, the stock looks expensive compared with its earnings and asset value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q3 2025 10-Q (period ended 2025-03-31) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer